Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.

[1]  S. Fox,et al.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy , 2004, Investigational New Drugs.

[2]  K. Tanikawa,et al.  Serum Vascular Endothelial Growth Factor Levels in Various Liver Diseases , 2004, Digestive Diseases and Sciences.

[3]  H. Joensuu,et al.  Serum VEGF levels in women with a benign breast tumor or breast cancer , 2004, Breast Cancer Research and Treatment.

[4]  E. van Marck,et al.  Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study , 2004, Angiogenesis.

[5]  R. Miceli,et al.  Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications , 2004, Angiogenesis.

[6]  M. Toi,et al.  Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression , 2004, Breast Cancer Research and Treatment.

[7]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[8]  E. van Marck,et al.  Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia , 2001, The Journal of pathology.

[9]  E. van Marck,et al.  Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node‐negative breast cancer patients , 2001, Histopathology.

[10]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[11]  M. Schindl,et al.  Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  D. Ruiter,et al.  Lack of lymphangiogenesis despite coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. , 2001, Investigative Ophthalmology and Visual Science.

[13]  G. Pruneri,et al.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.

[14]  K. Sugiyama,et al.  Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. , 2001, European journal of cancer.

[15]  S. Fox,et al.  Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. , 2001, The Lancet. Oncology.

[16]  E. van Marck,et al.  Early distant relapse in ‘node‐negative’ breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour , 2001, The Journal of pathology.

[17]  Tesshi Yamada,et al.  Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma , 2001, The Journal of pathology.

[18]  P. Carmeliet,et al.  Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.

[19]  F. Fabris,et al.  Validation of Blood Collection Procedures for the Determination of Circulating Vascular Endothelial Growth Factor (VEGF) in Different Blood Compartments , 2001, The International journal of biological markers.

[20]  C. West,et al.  Tumor vascularity: a histological measure of angiogenesis and hypoxia. , 2001, Cancer research.

[21]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Gasparini,et al.  Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. , 2001, Critical reviews in oncology/hematology.

[23]  C. N. Lee,et al.  Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. , 2001, Gynecologic oncology.

[24]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[25]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[26]  M. Schindl,et al.  Lymphatic microvessel density as a novel prognostic factor in early‐stage invasive cervical cancer , 2001, International journal of cancer.

[27]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Fox,et al.  The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[30]  H. Fukuda,et al.  Anatomic distribution of intraprostatic lymphatics: Implications for the lymphatic spread of prostate cancer—A preliminary study , 2000, The Prostate.

[31]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[32]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[33]  C. Fujiyama,et al.  Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis , 2000, BJU international.

[34]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[35]  R Bicknell,et al.  Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. , 2000, Cancer research.

[36]  S. Dirnhofer,et al.  Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells , 2000, The Lancet.

[37]  K. Alitalo,et al.  Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. , 2000, The American journal of pathology.

[38]  M J O'Hare,et al.  Linking gene expression patterns to therapeutic groups in breast cancer. , 2000, Cancer research.

[39]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[40]  S. Fox,et al.  Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39 , 2000, British Journal of Cancer.

[41]  R. Jain,et al.  Vasculogenic mimicry: how convincing, how novel, and how significant? , 2000, The American journal of pathology.

[42]  G. Gastl,et al.  Thrombocytes Are the Major Source for Soluble Vascular Endothelial Growth Factor in Peripheral Blood , 2000, Oncology.

[43]  R. Henriksson,et al.  p53 and vascular‐endothelial‐growth‐factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma , 2000, International journal of cancer.

[44]  W Vach,et al.  The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  K. Alitalo,et al.  Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors , 1999, Cancer.

[46]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[47]  J. Dixon,et al.  Reproducibility of microvessel counts in breast cancer specimens , 1999, British Journal of Cancer.

[48]  A. Giatromanolaki,et al.  Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: correlation with p53 and angiogenic factor expression. , 1999, Cancer research.

[49]  S. Singer,et al.  Different patterns of angiogenesis in sarcomas and carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  L. Ellis,et al.  Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. , 1999, Cancer research.

[51]  L. Hefler,et al.  Serum concentrations of vascular endothelial growth factor in vulvar cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  R. Henriksson,et al.  Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? , 1999, British Journal of Cancer.

[53]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[54]  C. Zornig,et al.  Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma , 1999, Journal of Cancer Research and Clinical Oncology.

[55]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[56]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[57]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[58]  O. Ogawa,et al.  Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma , 1999, Japanese journal of cancer research : Gann.

[59]  R. Paridaens,et al.  Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[61]  H. Caffier,et al.  Diagnostic value of serum VEGF in women with ovarian tumors. , 1999, Anticancer research.

[62]  S. Ménard,et al.  Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[63]  L. Dinkelborg,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A High-Affinity Human Antibody That Targets Tumoral Blood Vessels , 1999 .

[64]  M. Volm,et al.  Biological characterization of subgroups of squamous cell lung carcinomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[66]  H. Tsuda,et al.  Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[67]  R. Salgado,et al.  Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients , 1999, British Journal of Cancer.

[68]  A. Gadducci,et al.  Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. , 1999, Anticancer research.

[69]  P. Vermeulen,et al.  Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. , 1999, The cancer journal from Scientific American.

[70]  J A Beliën,et al.  Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. , 1999, Journal of clinical pathology.

[71]  H. Joensuu,et al.  Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  D. Jackson,et al.  LYVE-1, a New Homologue of the CD44 Glycoprotein, Is a Lymph-specific Receptor for Hyaluronan , 1999, The Journal of cell biology.

[73]  S. Kumar,et al.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.

[74]  E. Tschachler,et al.  Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. , 1999, The American journal of pathology.

[75]  M. Mildner,et al.  Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[76]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[77]  S. Campbell,et al.  Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow , 1999, Clinical endocrinology.

[78]  M. Karkkainen,et al.  Vascular endothelial growth factor receptor-3. , 1999, Current topics in microbiology and immunology.

[79]  D. Marmé,et al.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease , 1999, Cancer.

[80]  A. Larsson,et al.  Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas. , 1999, Anticancer research.

[81]  I. Hyodo,et al.  Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. , 1998, European journal of cancer.

[82]  B. Keyt,et al.  Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * , 1998, The Journal of Biological Chemistry.

[83]  E Biganzoli,et al.  Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  P. Drew,et al.  Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? , 1998, British Journal of Cancer.

[85]  R. Henriksson,et al.  Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  J. Foekens,et al.  Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  N. Voelkel,et al.  In vitro release of vascular endothelial growth factor during platelet aggregation. , 1998, The American journal of physiology.

[89]  K. Alitalo,et al.  Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. , 1998, The American journal of pathology.

[90]  P. Vermeulen,et al.  Vascular endothelial cell growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle. , 1998, European journal of cancer.

[91]  S. Uccini,et al.  Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma. , 1998, European journal of cancer.

[92]  A. Kaider,et al.  Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. , 1998, British Journal of Cancer.

[93]  R. Brekken,et al.  Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.

[94]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[95]  John,et al.  Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[97]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[98]  M. Bottomley,et al.  Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. , 1998, Clinical science.

[99]  R. Klemke,et al.  Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998, The Journal of cell biology.

[100]  S. Schnitt,et al.  Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[101]  E. Ingham,et al.  Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.

[102]  K. Tanikawa,et al.  Circulating Vascular Endothelial Growth Factor in Patients With Colorectal Cancer , 1998, American Journal of Gastroenterology.

[103]  H. Verheul,et al.  Platelet: transporter of vascular endothelial growth factor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[104]  M Buyse,et al.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. , 1997, The American journal of pathology.

[105]  G. Schaffner,et al.  Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. , 1997, American Journal of Pathology.

[106]  B. Nielsen,et al.  Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[107]  A. Kaider,et al.  Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease‐free survival , 1997, International journal of cancer.

[108]  E. van Marck,et al.  Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density. , 1997, Microvascular research.

[109]  U. Weidle,et al.  Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. , 1997, The American journal of pathology.

[110]  K. Alitalo,et al.  Serum vascular endothelial growth factor is often elevated in disseminated cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  Y. Yazaki,et al.  Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. , 1997, Clinical science.

[112]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[113]  J. Robb,et al.  Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  E. Rønne,et al.  Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma. , 1997, Human pathology.

[115]  O. Vinante,et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.

[116]  P. Vermeulen,et al.  Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. , 1997, British Journal of Cancer.

[117]  A. Nicholson,et al.  Angiogenesis in primary lung cancer and lung secondaries. , 1996, European journal of cancer.

[118]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[119]  G. Hubens,et al.  Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[120]  M. Toi,et al.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[122]  S. Hirohashi,et al.  Fibrotic Focus in Invasive Ductal Carcinoma: An Indicator of High Tumor Aggressiveness , 1996, Japanese journal of cancer research : Gann.

[123]  M. Toi,et al.  Quantitative analysis of vascular endothelial growth factor in primary breast cancer , 1996, Cancer.

[124]  R. Jain,et al.  Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. , 1996, Microvascular research.

[125]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[126]  N. Weidner,et al.  Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[127]  A. Harris,et al.  The increased expression of adhesion molecules ICAM‐3, E‐ and P‐selectins on breast cancer endothelium , 1995, The Journal of pathology.

[128]  A. Harris,et al.  Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis , 1995, The Journal of pathology.

[129]  A. Cochran,et al.  Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. , 1995, The American journal of pathology.

[130]  N. Weidner.  Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[131]  P. Wesseling,et al.  Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme: An Immuno‐light and Immuno‐electron Microscopic Study , 1995, Journal of neuropathology and experimental neurology.

[132]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[133]  D. Elder,et al.  Tumour vascularity is not a prognostic factor for cutaneous melanoma , 1994, The Lancet.

[134]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[135]  W. Kolch,et al.  Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.

[136]  N. Weidner,et al.  Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. , 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[137]  R Bicknell,et al.  Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.

[138]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[139]  S. Kato.  HISTOCHEMICAL LOCALIZATION OF 5′-NUCLEOTIDASE IN THE LYMPHATIC ENDOTHELIUM , 1990 .

[140]  Austin Brown.  SI UNITS , 1975, The Lancet.

[141]  M. Wachstein,et al.  THE HISTOCHEMICAL DISTRIBUTION OF 5-NUCLEOTIDASE AND UNSPECIFIC ALKALINE PHOSPHATASE IN THE TESTICLE OF VARIOUS SPECIES AND IN TWO HUMAN SEMINOMAS , 1954, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.